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INTRODUCTION
Type 1 diabetes mellitus (DM1) is thought to involve
chronic inflammation, which is manifested by the activa-
tion and expression of different inflammatory mediators
[1]. As a result, various diabetic complications develop
leading to increased mortality and morbidity.
IL-12 is a proinflammatory cytokine produced
by antigen presenting cells in response to PAMPs
(pathogen-associated molecular patterns) and DAMPs
(danger-associated molecular patterns). It induces the
polarization of the immune response towards Th1
profile, which protects against intracellular pathogens
[2, 3]. IL-12 has been implicated in the pathogenesis
of type 1 diabetes in the NOD (non-obese diabetic)
mouse [4]. Alleva et al. showed that macrophages
from NOD mice produced more IL-12 than NOR
(non-obese resistant) mice macrophages [5]. A link
between IL-12 and type 1 diabetes was also sug-
gested in humans. Glucose-stimulated PBMCs (pe-
ripheral blood mononuclear cells) from healthy sub-
jects produced more IL-12 than resting, unstimulated
cells [6]. What’s more, the production of IL-12 did
not change even after insulin treatment [6]. Similar
effect was seen in patients with type 2 diabetes. The
LPS-stimulated PBMCs under glucose treatment pro-
duced elevated level of IL-12 [7]. Furthermore, it
was shown that patients with longstanding DM1
show increased levels of IL-12 in both serum and
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Abstract—Type 1 diabetes is thought to involve chronic inflammation, which is manifested by the acti-
vation and expression of different inflammatory mediators. IL-12 and IL-18 are two cytokines that have
been shown to exert strong proinflammatory activity and have been implicated in the pathogenesis of type
1 diabetes in mice and humans. The overproduction of proinflammatory mediators is controlled by spe-
cialized T cell subset, namely regulatory T cells that express FOXP3 transcription factor. Since IL-12 and
IL-18 mediate inflammatory response and Tregs exhibit anti-inflammatory potential, we aimed to examine
their reciprocal relationship in patients with type 1 diabetes. The study group consisted of 47 children d-
iagnosed with type 1 diabetes and 28 healthy individuals. Serum levels of IL-12 and IL-18 were measured
by ELISA, and the peripheral blood CD4+CD25high FOXP3+ regulatory T cell frequencies were analyzed
by flow cytometry. Patients with type 1 diabetes had a decreased percentage of circulating
CD4+CD25highFOXP3+ Tregs in comparison to their healthy counterparts. In addition, they produced
more IL-12 and IL-18 than children from the control group. Concentrations of these cytokines positively
correlated with one another, as well as with CRP and HbA1c. Moreover, the negative association between
IL-12, IL-18, CRP serum levels, and the frequency of regulatory CD4+CD25highFOXP3+ Tregs was
observed. IL-12 and IL-18 may have direct or indirect impact on regulatory T cell subset, which may
contribute to their reduced frequency in peripheral blood of patients with type 1 diabetes mellitus.
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aqueous humor [8]. The latter may provide an evi-
dence for the involvement of IL-12 in pathogenesis
of late diabetic microvascular complications.
IL-18 belongs to the IL-1 superfamily of cytokines
and similarly to IL-1 it is synthesized as inactive precursor
and is secreted when appropriate cleaving enzymes are
present [9]. In synergy with IL-12, IL-18 activates polari-
zation of Th1 cells, augments activity of NK cells, and
induces IFN-γ production [10]. IL-18 was shown to play a
role in pathogenesis of inflammatory diseases such as
thyroid destruction in Hashimoto’s thyroiditis [11], rheu-
matoid arthritis [12, 13], allergy, asthma [14, 15], and
Crohn’s disease [16]. Some authors also linked IL-18 or
its receptor polymorphism with type 1 diabetes [17–21].
Furthermore, studies done by others showed that IL-18
serum concentrations are elevated in patients with type 2
diabetes [22, 23] and/or diabetic nephropathy [24, 25].
Regulatory T cells (Tregs) play a crucial role in the
maintenance of immune homeostasis in controlling auto-
immunity and inflammation. They are responsible for sup-
pressing the excessive ability of different cells to proliferate
and/or produce proinflammatory cytokines [26, 27]. They
are characterized by the coexpression of CD4, CD25, and a
t r a n s c r i p t i o n f a c t o r F O X P 3 , t h u s t h e
CD4+CD25highFOXP3+ is the most widely accepted
phenotype of Tregs [28, 29]. Defects in Tregs have been
reported by us and others in several autoimmune/
inflammatory diseases such as multiple sclerosis,
rheumatoid arthritis, systemic lupus erythematosus, or
type 1 diabetes [27, 30–33]. Moreover, it was shown that
depletion of Tregs deteriorated nephropathy in non-insulin-
dependent diabetic mice, while adoptive transfer of Tregs
exerted protective effect on kidneys [34]. Immune
response studies in animal models of kidney injury also
suggested the protective role for the CD4+FOXP3+
regulatory T cell subset [35–37].
Since IL-12 and IL-18 mediate inflammatory re-
sponse and Tregs exhibit anti-inflammatory potential, we
aimed to examine the relation between them in patients
with type 1 diabetes. It is particularly important because the
disease can progress into clinically manifested vascular
complications such as retinopathy or nephropathy.
MATERIALS AND METHODS
Subjects
The study group consisted of 47 young patients (mean
age; 14.25±3.5 years) diagnosed with type 1 diabetes that
were recruited from Clinic of Pediatrics, Department of
Diabetology and Endocrinology Medical University of
Gdańsk. Type 1 diabetes was defined according to the
criteria of the American Diabetes Association. Patients
with microvascular complications, as well as those with
coexisting autoimmune, chronic, and acute inflammatory
diseases were excluded from the study. The mean duration
of the disease was 7.39±3.8 years. In all examined patients,
the C-peptide levels were below 0.5 ng/ml. All patients
were treated with humanized insulin at doses of 0.87±
0.2 mg/kg. At the time of sampling, a blood glucose level
along with biochemical measurement of renal function,
lipid status, C-reactive protein (CRP), and glycosylated
hemoglobin (HbA1c) were monitored.
The control group consisted of 28 age and sex-
matched individuals recruited during control visits in out-
patient clinic. No signs of autoimmune, chronic, inflam-
matory, and neoplastic disease at the time of sampling and
no evidence of DM1 in their families were disclosed as
confirmed bymedical records, laboratory examination, and
laboratory tests.
All subjects gave informed consent and the study
followed the principles of the Declaration of Helsinki and
was approved by The Ethics Committee of The Medical
University of Gdańsk.
Isolation and Flow Cytometric Analysis of Peripheral
Blood CD4+CD25high FOXP3+ Regulatory T cells
Heparinised venous blood samples were collected
and used to isolate PBMCs (peripheral blood mononuclear
cells) by density gradient preparation over Ficoll-
Uropoline. 1 × 106 freshly isolated PBMCs were destined
for flow cytometric staining. Cells were stained with anti-
CD4 (IgG1,κ mouse Pe/Cy5, Clone RPA-T4, BioLegend,
USA) and anti-CD25 (IgG1, ĸ mouse PE, Clone BC96,
BioLegend, USA) antibodies and incubated for 30 min in
the dark, fixed, and stained for intracellular expression of
FOXP3 (IgG1,κ mouse Alexa-Fluor 488, Clone 206D,
BioLegend, USA). Measurements were performed on the
LSRII flow cytometer (BD Biosciences). Dead cells were
excluded by forward and side scatter. Positive signal for
each staining was established using appropriate isotype
control. Data were analyzed by FACSDiva 6.0 Software
(Becton Dickinson, USA).
Determination of Serum IL-12 and IL-18 Levels
Serum levels of IL-12 and IL-18 were measured by
ELISA method (Quantikine R&D Systems, Minneapolis,
Minn., USA and Quantitative test, MBL International,
1514 Ryba-Stanisławowska, Rybarczyk-Kapturska, Myśliwiec, and Myśliwska
USA, respectively). According to the manufacturer proto-
col, minimum detectable concentrations were determined
by the manufacturer as 0.1 pg/ml for IL-12 and 12.5 pg/ml
for IL-18.
Intra-assay coefficient of variation ranged between
2.5–4.9 % (IL-12) and 5.03–9.92 % (IL-18). The inter-
assay coefficient of variation was 7.6–12.6 % (IL-12) and
6.25–10.07 % (IL-18). The results were read on the auto-
mated plate reader (MultiscanMCC/340, Labsystems, Hel-
sinki, Finland).
Statistical Analysis
The results were analyzed using the Statistica, ver.
10.0 (StatSoft Inc, USA). For comparison of the skew-
distributed variables, non-parametricMann-WhitneyU test
was applied. Spearman’s correlations were used to com-
pare the associations between analyzed parameters. The
level of significance was set at p≤0.05.
RESULTS
Clinical Characteristics of the Study Groups
The basic characteristic of children enrolled in the
study is presented in Table 1. No significant difference
was detected between diabetic and control group by means
of age, gender, and BMI. Patients with type 1 diabetes had
significantly higher levels of HbA1c, as well as CRP in
comparison to the age and sex-matched healthy individuals
from the control group.
Serum Concentrations of IL-12 and IL-18 in Patients
with Type 1 Diabetes
Patients with type 1 diabetes showed statistically
higher serum levels of IL-12 and IL-18 than children from
the control group (Table 2). Concentrations of these cyto-
kines positively correlated with CRP level (Fig. 1a, b) as
well as demonstrated a positive correlation with one an-
other (Fig. 1c). As to the association of analyzed cytokines
with HbA1c, we found correlation only in case of IL-12
(Fig. 1d). We could not found significant correlation be-
tween serum IL-18 and HbA1c (Fig. 1e).
Peripheral Blood CD4+CD25highFOXP3+ Regulatory T
Cell Counts in Patients with Type 1 Diabetes
Peripheral blood from the two groups of children was
analyzed with regard to the frequency of CD4+CD25high T
cells expressing FOXP3 transcription factor. As shown in
Figs. 2 and 3, the frequencies of circulat ing
CD4+CD25highFOXP3+ Tregs were significantly lower in
DM1 patients in comparison to their healthy counterparts
from the control group.
Our study was extended by performing the correlation
analysis between frequency of peripheral blood Tregs and
serum level of CRP, IL-12, and IL-18 in DM1 group. The
results of this analysis are presented in Table 3. A significant
inverse association between the percentage of regulatory
CD4+CD25highFOXP3+ Tregs and serum level of CRP, IL-
12, and IL-18 (R=−0.69; R=−0.42; and R=−0.66,
respectively) was observed.
DISCUSSION
Chronic inflammation in type 1 diabetes has been
confirmed by the number of studies [38–41]. Several pro-
inflammatory cytokines were shown to be elevated in
serum of diabetic patients with a new onset of diabetes or
a longstanding disease [38, 42, 43]. IL-12 and IL-18 are
additional two cytokines that have been shown to exert
strong proinflammatory activity and that synergize in ac-
tion with each other, as well as with TNF-α or IL-1 [44]. In
the present study, patients with type 1 diabetes had higher
serum level of IL-12 and IL-18 in comparison to the
healthy subjects from the control group. What’s more,
















14.25±3.58 26/21 7.39±3.8 18.4±3.3 8.7±2.26 17.7±6.9 2.41±1.89
healthy (n=28) 15.6±1.7 16/14 – 17.8±3.2 5.2±0.1 – 0.7±0.15
p* 0.7 0.8 0.2 0.001 0.0002
Data are shown as mean ± SD
*The significance between DM1 patients and healthy subjects
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serum levels of IL-12 and IL-18 were positively associated
with CRP, which is one of the most important biomarkers
of chronic inflammation [40, 42]. Recently, Devaraj et al.
showed that CRP has the ability to polarize human mono-
cytes towards proinflammatory M1 phenotype [45]. The
overproduction of CRP may disrupt the balance between
M1 and M2 macrophages and thus induce the production
of IL-12 and/or IL-18 in an indirect way [10]. Our results
demonstrating increased circulating IL-12 and IL-18 con-
centrations in DM1 patients are consistent with the studies
done by Blazhev et al. [46], which showed that the levels
of IL-12 and IL-18 have been increasing along with DM1
progression [46]. IL-12 as well as IL-18 may have a role in
pathophysiology of the late microvascular complications;
however, studies have yielded contradictory findings so far
[24, 47, 48].
Besides CRP, a positive relationship between IL-12
serum level and glycosylated hemoglobin was found.
However, we found no significant correlation between
plasma IL-18 and HbA1c. HbA1c is an indicator of meta-
bolic control and is measured to provide an index of
average blood glucose for the previous 3 to 4 months.
Esposito et al. have shown that acute hyperglycemia, con-
trary to chronic state, raised IL-18 level to a peak at 2 h,
which returned to basal value after next hour [49]. This
could explain the observed lack of correlation between
concentration of IL-18 and HbA1c in our patient group.
Similar findings regarding no association between serum
Table 2. Serum Level of IL-12 and IL-18
DM1 patients Control group p
IL-12
(pg/ml)
1.2 (0.2/3.8) 0.1 (0/0.4) 0.00001
IL-18
(pg/ml)
64.8 (42.9/108.2) 44.4 (43.5/66.1) 0.006
The results are shown as median and 10/90 percentile. All the differences were calculated by the Mann-Whitney U test
Fig. 1. Relationship between serum level of IL-12, IL-18 CRP, and HbA1c in patients with type 1 diabetes. The levels of IL-12, IL-18 CRP, andHbA1c were
measured in the blood of DM1 children and correlated with each other. The Spearman test was used to calculate the strength of correlation. a The correlation
between IL-12 and CRP serum level in DM1 subjects (R=0.39; p<0.05); b The correlation between IL-18 and CRP serum level in DM1 subjects (R=0.74; p
<0.05); c The correlation between IL-12 and IL-18 serum level in DM1 subjects (R=0.3; p>0.05). d The correlation between IL-12 and HbA1c in DM1
subjects (R=0.36; p<0.05); e The correlation between IL-18 and HbA1c level in DM1 subjects (R=0.2; p>0.05).
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IL-18 concentrations and the level of glycemic control
were reported by other groups [23, 50, 51]. However, there
are some studies with opposite results, suggesting that
elevated IL-18 levels could, at least in part, contribute to
the development of diabetic complications [47, 48]. This is
even more likely as the value of HbA1c is strongly associ-
ated with complications of diabetes [52]. DM1 patients
with poor glycemic control are characterized by elevated
serum level of TNF-α, so more intense inflammatory re-
sponse [24]. Importantly, IL-12, as well IL-18 were shown
to induce the synthesis of TNF-α which makes them
complications-accelerating indirect factors [48, 53]. In ad-
dition, IL-12 was found to be involved in the progression
of retinopathy [8] and CRP may upregulate its synthesis
[54], which is in agreement with our results.
In view of the facts that control of inflammatory
response is closely related to regulatory T cells, we’ve
decided to analyze the CD4+CD25highFOXP3+ T cell
subset in the context of IL-12 and IL-18 cytokine milleu
in DM1 patients. We found a decreased percentage of these
cells in peripheral blood of diabetic type 1 patients in
comparison to their healthy counterparts, but what’s more
Fig. 2. Representative staining of circulating CD4+CD25highFOXP3+ T cells in patient with type 1 diabetes and healthy individual. Fresh, resting PBMCs
from diabetic type 1 patients and healthy individuals were stained with antibodies against CD4, CD25, and FOXP3 molecules and analyzed using flow
cytometry. The gate was set on CD4+ CD25+ lymphocytes aBased on the CD4+CD25+ gate, cells were further gated based on CD25 and FOXP3 expression
and the frequency of CD4+CD25highFOXP3+ cells was determined b.
Fig. 3. Frequency of CD4+CD25highFOXP3+ T cells in peripheral blood
of diabetic type 1 patients and healthy individuals. Fresh, resting PBMCs
from diabetic type 1 patients (DM1) and healthy individuals were stained
with anti-CD4, anti-CD25, and anti-FOXP3 mAbs and then the frequency
of CD4+CD25highFOXP3+ cells among CD4+ lymphocytes was
determined using flow cytometry. The mean percentage of cells (25/75
percentiles) in DM1 and healthy group was 1.6 (1.1/2.3) and 6 (4.5/7.2),
respectively. Data were calculated with Mann-Whitney U test. Horizontal
lines represent the mean frequency of cells. **The percentage of cells
among peripheral blood CD4+ lymphocytes. *Indicates significant
difference versus healthy group (p=0.0001).
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interesting we observed the inverse association between
serum level of IL-12, IL-18, and frequencies of Tregs. It is
difficult to decide whether Tregs are unable to suppress
production of inflammatory cytokines, or IL-12/IL-18 has
detrimental effect on Tregs numbers. There are only few
published mouse model studies on the association between
IL-12/IL-18 cytokines and regulatory T cell subset.
A possible link between IL-12 and the induction of
Tregs was suggested by Morrow et al. [54], who showed
that IL-12 increased the number of splenic regulatory Tcells
in immunized mice [54]. Zhao et al. [55] also demonstrated
that IL-12 signaling pathway may have a role in regulation
of Tregs numbers. The authors showed that mice lackingβ2
chain of IL-12 receptor had more CD4+CD25− effector T
cells but fewer CD4+CD25+ Tregs thanwild-typemice upon
activation [55]. Previous studies by King et al. [56]
suggested that IL-12 acts directly on CD4+CD25− effector
T cells rather than Tregs. IL-12 restores CD4+CD25− T cell
activation, even in the presence of regulatory T cells [56]. In
other studies, IL-12 was shown to induce IFN-γ production
by Tregs in vitro and in vivo [57–59]. Induction of IFN-γ
expression by Tregs upon IL-12 treatment reduced Treg
numbers and expression of FOXP3 transcription factor
[57, 58]. Recent study by Zhao et al. [59] showed that IL-
12 increased IL-2R expression on effector T cells,
diminished its expression on Tregs, and decreased IL-2
production by effector T cells [59]. IL-2 is essential for the
maintenance of regulatory T cells [30]. Low level of IL-2
may contribute to reduced Treg proliferation, which perhaps
leads to their diminished numbers.
Similarly to IL-12, IL-18was shown to increase the ratio
of effector T cells to Tregs [60]. However, there are contra-
dictory results showing that IL-18 is essential for inducing
antigen-specific regulatory T cells and oral tolerance [61]. In
contrast to these data, Zeiser et al. [62] demonstrated that IL-
18 is not required for Treg expansion [62]. One of the know
feature of IL-18 is its ability to stimulate the Th17 cells [10].
Th17 cells are involved in the pathogenesis of inflammatory
and autoimmune diseases, and they also predominate in
patients with type 1 diabetes, which was shown by us and
others [63, 64]. Upregulated Th17 immune response may
have impact on Treg numbers.
In view of the limited data regarding the relation
between proinflammatory IL-12/IL-18 and regulatory T
cells, further studies in humans are needed to properly
verify this. However, the results of our analysis lead us to
conclude that patients with type 1 diabetes have enhanced
inflammatory response, which is manifested by increased
values of CRP, HbA1c, IL-12, and IL-18. These mediators
of inflammation may have direct or indirect impact on
regulatory T cell subset, which may contribute to their
reduced frequency in peripheral blood.
In the larger context, the data presented by us are
mainly observation, and future in vitro studies are needed
to determine the impact of IL-12 and IL-18 on Tregs
quantitative as well as qualitative changes.
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